Additionally, activating the cGAS–STING pathway can restrict tumor growth by inducing specific antitumor immunity [11]; therefore, preclinical research targeting the cGAS–STING pathway can pave the way for future translation into clinical trials, ultimately alleviating symptoms, improving the life quality of patients with various autoimmune or inflammatory disorders, and prolonging the life expectancy of patients with cancer. Here, CGAS is linked to neoplasm.